German health regulators have granted Northwest Biotherapeutics Inc (NASDAQ:NWBO) special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small US biotechnology company has not yet completed its late-stage trial of the immunotherapy. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 29.55% in last session and finished the day at $7.85. Traded volume was 6,155,092 million shares in the last session and the average volume of the stock remained 913.66 million shares. The beta of the stock remained 2.83. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) insider ownership is 9.86%.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said revenue this year will be higher, citing a reimbursement agreement for its drug Soliris. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rose 7.11 percent to $180.00 yesterday on volume of 2.60 million shares. The intra-day range of the stock was $170.83 to $180.82. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has a market capitalization of $35.61million.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its fourth quarter and full year 2013 financial results. Net loss for 2013 was $130.7 million, or basic and diluted net loss per share available to common stockholders of $1.32, compared with net loss for 2012 of $91.8 million, or basic and diluted net loss per share available to common stockholders of $1.28. Merrimack Pharmaceuticals Inc (NASDAQ:MACK)’s stock on Mar 10, 2014 reported an increase of 8.84% to the closing price of $5.91. Its fifty two weeks range is $2.05 -$7.09. The total market capitalization recorded $608.96 million. The overall volume in the last trading session was 2,819,394 million shares. In its share capital, Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has 102.41 million outstanding shares.

Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) is a biotechnology company. The Company’s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. On Monday, shares of Enzon Pharmaceuticals Inc (NASDAQ:ENZN) advanced 7.00% to close the day at $1.07. Company return on investment (ROI) is 0.10% and its monthly performance is recorded as 22.99%. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) quarterly revenue growth is 2.88%.